Brian Feroldi

Alexion Pharmaceuticals has been a biotech investor's dream stock for years and has created a fortune for patient investors. But with a strong product lineup and healthy pipeline, the future looks great, too.

The bears have been right about Keryx Pharmaceuticals stock so far this year -- should you sell today? Here are four reasons why selling may make sense.

Is the move meaningful, or just market noise?

This long-time sleepy stock has woken up recently on a flurry of good news. Does the future finally look bright for investors?

Gilead Sciences and Amgen are widely recognized as blue-chip biotech stocks. But which one has better is the better choice for income-seeking investors?

The global drugstore giant continues to treat investors well as solid earnings results propel the stock higher.

Investors continue to grow bullish on the prospects of its pending acquisition of Tribute Pharmaceuticals, but this Fool thinks there are reasons to be cautious.

Investors cheer a smaller than expected loss and wait patiently for news about regulatory approval of MM-398.

Investors who are looking for income stocks that don't require day to day attention should give these 3 stocks a look.

Investors remain bullish on Anika Therapeutic's prospects. Was the market right to bid up the stock in July?

Amarin wins a key court battle against the FDA, and investors bid the stock up on the positive news.

Updated clinical results for Chimerix's lead compound brincidofovir cause the stock to continue to outperform. Can the good times continue for Chimerix investors?

An increase in spending and an uptick in analyst activity weighed on the company's shares today.

Shares of the clinical-stage biotech are dropping today after the company reported second-quarter earnings.

The company's stock moves higher on strong revenue growth and expanded margins, but the company sharply reduces guidance.

Shares of this former high-flyer continue to move lower after reporting second quarter earnings.

Cardiovascular Systems stock fell hard today after the company reported revenue results below its guidance range.

Merge Healthcare is being bought out by Big Blue.

The company raised its growth estimates for the year, but a larger-than-expected loss is causing investors to bid the shares lower.

Advaxis stock continues to slide since peaking in price two months ago. What's behind the price decline, and can investors expect more pain in the future?